World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
48130
World Ranking
5951
National Ranking
65

Luc Dirix publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Luc Dirix sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 659 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Luc Dirix D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Luc Dirix sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Luc Dirix is affiliated with GZA Ziekenhuizen Campus Sint-Augustinus in Belgium and has contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research focuses prominently on Oncology, with particular emphasis on Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Surgery.

The scientist's main research topics cover:

  • Breast Cancer Treatment Studies
  • Cancer Cells and Metastasis
  • Medical Imaging and Pathology Studies
  • Cancer Immunotherapy and Biomarkers
  • Advanced Breast Cancer Therapies
  • Cancer Genomics and Diagnostics
  • Estrogen and related hormone effects

Selected recent publications by Luc Dirix include:

  • Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study, 2022, The Lancet Oncology
  • An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver, 2023, Nature Communications
  • Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity, 2020, Breast Cancer Research and Treatment
  • Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial, 2023, Clinical Cancer Research
  • Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy, 2023, Cancer Research Communications

Luc Dirix has published multiple articles in prominent scientific journals, frequently contributing to:

  • Clinical Cancer Research
  • Cancer Research
  • The Breast
  • The Lancet Oncology
  • Nature Communications

The scientist has collaborated regularly with the following coauthors:

  • François Bertucci
  • Patrick Neven
  • Steven Van Laere
  • Hans Wildiers
  • Ha-Linh Nguyen

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences

    Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna

  • Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

    Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

    François-Clément Bidard;François-Clément Bidard;Dieter Peeters;Tanja Fehm;Franco Nolé

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

    P. E. Vermeulen;G. Gasparini;S. B. Fox;Masakazu Toi

  • Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

    M Kaufmann;E Bajetta;L Y Dirix;L E Fein

  • Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

    Luc Y. Dirix;Istvan Takacs;Guy Jerusalem;Petros Nikolinakos

  • Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.

    P.B. Vermeulen;G. Gasparini;S.B. Fox;C. Colpaert

  • Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

    Harold J. Burstein;Yan Sun;Luc Y. Dirix;Zefei Jiang

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

    M. Aapro;P. A. Abrahamsson;J. J. Body;R. E. Coleman

  • Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.

    Roberto Salgado;Sara Junius;Ina Benoy;Peter Van Dam

  • International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

    S. Dawood;S. D. Merajver;P. Viens;P. B. Vermeulen

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

  • Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

    M. Brada;K. Hoang-Xuan;R. Rampling;P. Y. Dietrich

  • Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

    Michael R. Migden;Alexander Guminski;Ralf Gutzmer;Luc Dirix

  • Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    Sara A. Hurvitz;Luc Dirix;Judit Kocsis;Giulia V. Bianchi

Frequent Co-Authors

Peter B. Vermeulen
Peter B. Vermeulen University of Antwerp
Eric Van Marck
Eric Van Marck University of Antwerp
Caroline Seynaeve
Caroline Seynaeve Erasmus University Rotterdam
John W.M. Martens
John W.M. Martens Erasmus University Rotterdam
John M. S. Bartlett
John M. S. Bartlett University of Toronto
Stefan Sleijfer
Stefan Sleijfer Erasmus University Rotterdam
Roberto Salgado
Roberto Salgado Peter MacCallum Cancer Centre
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Cornelis J.H. van de Velde
Cornelis J.H. van de Velde Leiden University Medical Center
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA can open the door to a wide range of online health-related degrees and career paths. Many healthcare roles now offer flexible online programs, making it easier for students to gain advanced knowledge without relocating.

For nurses seeking leadership positions, pursuing one of the best online bsn to dnp programs is a great way to advance from bedside care to executive or academic roles. Those interested in pharmaceuticals should compare online pharmacy school cost to make informed financial decisions before committing to a program.

If you’re drawn to health data and technology, there are accredited rhit programs online that prepare you for managing patient records and health information systems. Additionally, for those seeking a quick entry into healthcare administration, several affordable medical billing and coding programs can be completed entirely online.

Choosing the right online pathway depends on your interests, career goals, and budget. By exploring related online degrees, future healthcare professionals can find the best fit for their needs while maintaining flexibility in their studies.

Best Scientists Citing Luc Dirix

Trending Scientists

Recently Published Articles